BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26629945)

  • 1. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
    Suenaga M; Akiyoshi T; Shinozaki E; Fujimoto Y; Matsusaka S; Konishi T; Nagayama S; Fukunaga Y; Kawakami K; Yokokawa T; Sugisaki T; Ueno M; Yamaguchi T
    Anticancer Res; 2018 Mar; 38(3):1741-1747. PubMed ID: 29491111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
    Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
    Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
    Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
    Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
    Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
    Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
    Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
    N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.
    Yamazaki K; Matsumoto S; Imamura CK; Yamagiwa C; Shimizu A; Yoshino T
    Jpn J Clin Oncol; 2020 Feb; 50(2):122-128. PubMed ID: 31665356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
    Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
    Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
    Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
    Sha A; Abadi S; Gill S
    J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
    Danno K; Hata T; Tamai K; Fujie Y; Ide Y; Kim HM; Ohnishi T; Morita S; Yoshioka S; Kudo T; Nishimura J; Matsuda C; Akamatsu H; Mizushima T; Nezu R; Doki Y; Mori M; ;
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):777-785. PubMed ID: 28825216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
    Ouali K; Turpin A; Neuzillet C; Rousseau B; Garcia-Larnicol ML; Tournigand C; Samalin E; Taieb J; André T; Cohen R
    Clin Colorectal Cancer; 2021 Mar; 20(1):79-83.e4. PubMed ID: 33281064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
    André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
    Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
    J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
    JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.